3.4 News

August 2, 2018

Tempus to Participate in the NCI-MATCH Clinical Trial

Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial CHICAGO, Aug. 02, 2018 (GLOBE NEWSWIRE) — Tempus announced today that it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analys...

May 8, 2018

Tempus Announces New Initiative to Support Physicians Efforts to Deliver Personalized Medicine

CHICAGO, May 08, 2018 (GLOBE NEWSWIRE) — Tempus today announced a new initiative that will allow physicians to sequence a second patient sample without additional charge, removing a barrier that oftentimes stands in the way of a patient being sequenced.The Tempus xT panel analyzes 595 genes relevant to th...

March 20, 2018

Tempus Announces Additional $80 Million in Financing

Chicago, March 20 – Tempus announced today it has raised an additional $80M in financing. The round included existing investors, New Enterprise Associates and Revolution Growth, along with new investors Kinship Trust Company and funds advised by T. Rowe Price Associates, Inc. The additional funds will be used to fur...

February 22, 2018

Tempus Launches Tempus xE, Whole Exome Sequencing to Empower Data-Driven Cancer Care and Research

CHICAGO, Feb. 22, 2018 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, has launched a new genomic sequencing panel, Tempus xE, which analyzes the whole exome in a CLIA/CAP validated assay...

February 16, 2018

Tempus and the Parker Institute for Cancer Immunotherapy Work Together to Analyze Data to Help Inform Immunotherapy Treatments

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Parker Institute for Cancer Immunotherapy will work together to analyze clinical and molecular data to better determine which patients will have a positive res...

January 31, 2018

Precision Medicine World Conference

Eric Lefkofsky, founder and CEO of Tempus discusses the tools and approach necessary to usher in an era of personalized medicine.

January 25, 2018

Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients

CHICAGO, Jan. 25, 2018 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced a collaboration with NYU School of Medicine aimed at improving outcomes for patients diagnosed with pancreatic cancer.Pa...

January 4, 2018

Tempus and Vanderbilt-Ingram Cancer Center Announce Data Initiative to Improve Outcomes for Cancer Patients

CHICAGO, Jan. 04, 2018 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients. As part of t...

December 21, 2017

CancerLinQ Engages Leading Technology Companies Tempus and Precision HealthAI to Accelerate Data-Driven Insights to Oncologists and the Cancer Care Community

Alexandria, Va.— CancerLinQ LLC and the data services companies Tempus and Precision HealthAI announced today they have entered into an agreement that will accelerate development and delivery of high-quality, de-identified clinical databases for use by CancerLinQ®, its oncologist subscribers, partners, and the broader cancer community. The agreement wil...

December 11, 2017

Tempus unveils a standalone tool for structuring clinical data at scale

Why do some patients respond to immuno-oncology drugs when others don’t? It’s one of many million-dollar questions in medicine that confound companies, researchers, and clinicians alike. And the really frustrating part? We know where many of the answers lie. They’re trapped in electroni...

Show More